Trishula Therapeutics kickstarts Phase 2 study of TTX-030, a compound directed against CD39, in initial treatment of patients with advanced pancreatic cancer.

Phase III EMERALD-1 trial reveals Imfinzi combined with bevacizumab achieved primary objective by improving progression-free survival in advanced liver cancer patients who qualify for embolisation.

Eccogene acquires unique licensing rights from AstraZeneca to advance and market ECC5004, a small molecule GLP-1 receptor agonist, for cardiovascular metabolic conditions.

Allgenesis reports promising initial safety and effectiveness results for AG-73305 phase 2a trial tackling Diabetic Macular Edema, presented at the American Academy of Ophthalmology.

Takeda has announced FDA approval for its oral drug, FRUZAQLA™ (fruquintinib), designed to treat adults with metastatic colorectal cancer who have previously received chemotherapy, anti-VEGF, and applicable anti-EGFR therapies.

The EU has sanctioned VANFLYTA®, the initial FLT3 inhibitor tailored for recently identified patients with FLT3-ITD positive AML.

Orum Therapeutics has announced a final agreement with Bristol Myers Squibb for the acquisition of its ORM-6151 program.

BioRay introduces the initiation of its Phase I clinical trial with the first patient for BRY812, a new LIV-1 focused antibody drug conjugate.

Ventyx Biosciences reports outcomes of the second phase study of VTX958 in moderate-to-severe plaque psoriasis patients and delivers a company update.

Monte Rosa Therapeutics unveils preclinical findings. The research indicates that MRT-6160, a VAV1-specific molecular glue breaker, may be effective in treating immune-based and inflammatory disorders.

At SITC 2023, ENB Therapeutics showcased preliminary findings from the first phase of its ENBOLDEN-101 trial for platinum-resistant ovarian cancer.

Qualigen Therapeutics reports the initial dosage in the Phase 1a QN-302 Clinical Study for Advanced or Metastatic Solid Tumors has been administered to the first patient.